메뉴 건너뛰기




Volumn 37, Issue 10, 2003, Pages 1518-1521

AUIC in humans: A fact-based discussion

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFMENOXIME; CEFTAZIDIME; CIPROFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

EID: 0141446341     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D337     Document Type: Editorial
Times cited : (3)

References (19)
  • 1
    • 0141781235 scopus 로고    scopus 로고
    • Fluoroquinolone AUIC break-points and the link to bacterial killing rates. Part 2: Human trials
    • DOI 10.1345/aph.1C419
    • Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break-points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003;37:1478-88. DOI 10.1345/aph.1C419
    • (2003) Ann Pharmacother , vol.37 , pp. 1478-1488
    • Schentag, J.J.1    Meagher, A.K.2    Forrest, A.3
  • 2
    • 0027258453 scopus 로고
    • Population pharmacokinetic methods to optimise antibiotic effects
    • Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimise antibiotic effects. Drug Invest 1993;5:256-68.
    • (1993) Drug Invest , vol.5 , pp. 256-268
    • Amsden, G.W.1    Ballow, C.H.2    Schentag, J.J.3
  • 5
    • 0022000170 scopus 로고
    • Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia
    • Schentag JJ, Vari AJ, Winslade NE, Swanson DJ, Smith IL, Simons GW, et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985;78:34-41.
    • (1985) Am J Med , vol.78 , pp. 34-41
    • Schentag, J.J.1    Vari, A.J.2    Winslade, N.E.3    Swanson, D.J.4    Smith, I.L.5    Simons, G.W.6
  • 6
    • 0034870049 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
    • Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231-44.
    • (2001) Clin Ther , vol.23 , pp. 1231-1244
    • Smith, P.F.1    Ballow, C.H.2    Booker, B.M.3    Forrest, A.4    Schentag, J.J.5
  • 7
    • 0033837432 scopus 로고    scopus 로고
    • Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells
    • Garcia I, Pascual A, Ballesta S, Perea EJ. Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. Int J Antimicrob Agents 2000;15:201-5.
    • (2000) Int J Antimicrob Agents , vol.15 , pp. 201-205
    • Garcia, I.1    Pascual, A.2    Ballesta, S.3    Perea, E.J.4
  • 8
    • 0036128763 scopus 로고    scopus 로고
    • Effects of gati-floxacin on phagocytosis, intracellular killing and oxidant radical production by human polymorphonuclear neutrophils
    • Braga PC, Dal Sasso M, Bovio C, Zavaroni E, Fonti E. Effects of gati-floxacin on phagocytosis, intracellular killing and oxidant radical production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 2002;19:183-7.
    • (2002) Int J Antimicrob Agents , vol.19 , pp. 183-187
    • Braga, P.C.1    Dal Sasso, M.2    Bovio, C.3    Zavaroni, E.4    Fonti, E.5
  • 9
    • 0037695856 scopus 로고    scopus 로고
    • Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae (SP)
    • San Diego, September 27-30
    • Kiem S, Craig WA. Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae (SP) (abstract A-492). In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
    • (2002) Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Kiem, S.1    Craig, W.A.2
  • 11
    • 0035867022 scopus 로고    scopus 로고
    • What have we learned from pharmacokinetic and pharmacodynamic theories?
    • Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(supple 1):S39-46.
    • (2001) Clin Infect Dis , vol.32 , Issue.SUPPL. 1
    • Schentag, J.J.1    Gilliland, K.K.2    Paladino, J.A.3
  • 12
    • 0034812780 scopus 로고    scopus 로고
    • Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
    • Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer H, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2793-2797
    • Ambrose, P.G.1    Grasela, D.M.2    Grasela, T.H.3    Passarell, J.4    Mayer, H.5    Pierce, P.F.6
  • 13
    • 0031474148 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
    • Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(suppl A):45-57.
    • (1997) J Antimicrob Chemother , vol.40 , Issue.SUPPL. A , pp. 45-57
    • Forrest, A.1    Chodosh, S.2    Amantea, M.A.3    Collins, D.A.4    Schentag, J.J.5
  • 16
    • 0032515371 scopus 로고    scopus 로고
    • Antibiotic dosing - Does one size fit all?
    • Schentag JJ. Antibiotic dosing - does one size fit all? JAMA 1998; 279:159-60.
    • (1998) JAMA , vol.279 , pp. 159-160
    • Schentag, J.J.1
  • 17
    • 0034959819 scopus 로고    scopus 로고
    • Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention
    • American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
    • (2001) Am J Respir Crit Care Med , vol.163 , pp. 1730-1754
  • 18
    • 0031940776 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    • Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 521-527
    • Thomas, J.K.1    Forrest, A.2    Bhavnani, S.M.3    Hyatt, J.M.4    Cheng, A.5    Ballow, C.H.6
  • 19
    • 0037100548 scopus 로고    scopus 로고
    • Why the AUC/MIC ratio should not be used to predict the effects of β-lactams
    • Mouton JW. Why the AUC/MIC ratio should not be used to predict the effects of β-lactams. Clin Infect Dis 2002;35:209-10.
    • (2002) Clin Infect Dis , vol.35 , pp. 209-210
    • Mouton, J.W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.